EANS-News: AGENNIX AG / Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Personnel

Planegg/Munich (Germany), Princeton, NJ and Houston, TX, July 20,
2011 (euro adhoc) - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced the appointment of Christine Boisclair as Senior Vice
President, Global Regulatory Affairs, reporting to Dr. Rajesh Malik,
Chief Medical Officer. In this position, Ms. Boisclair will lead all
global regulatory, quality and compliance activities for Agennix,
including regulatory filings for talactoferrin.

Rajesh Malik, M.D., Chief Medical Officer, said, "I am very pleased
to welcome Christine Boisclair to Agennix. She has a strong track
record of getting drugs approved in both Europe and the U.S.,
including a drug for non-small cell lung cancer. Her extensive
expertise in overseeing novel therapies through the regulatory review
process will be invaluable as we advance talactoferrin through
development and prepare for a potential regulatory filing if the
FORTIS-M trial is positive."

Ms. Boisclair has over twenty years of U.S. and European regulatory
affairs experience, covering both drugs and biologics in a variety of
therapeutic areas, including oncology and anti-infectives. She joins
Agennix from OSI Pharmaceuticals, Inc., where she worked for over ten
years in positions of increasing responsibility, most recently
serving as Vice President, Regulatory Affairs. At OSI, she built up
the regulatory affairs department and served as the regulatory lead
for the successful New Drug Application (NDA) for Tarceva®
(erlotinib) in non-small cell lung cancer (NSCLC), as well as the
subsequent supplemental NDAs for pancreatic cancer and NSCLC
maintenance. Prior to OSI, she worked at several biotechnology and
pharmaceutical companies, including Genzyme Corporation, GD Searle &
Co. and Glaxo Group Research. She holds a Bachelor of Science Honors
Degree in Biochemistry from York University, York, England.

About Agennix Agennix AG is a publicly listed biopharmaceutical
company that is focused on the development of novel therapies that
have the potential to substantially improve the length and quality of
life of critically ill patients in areas of major unmet medical need.
The Company's most advanced program is talactoferrin, an oral
immunotherapy that has demonstrated activity in randomized,
double-blind, placebo-controlled Phase II studies in non-small cell
lung cancer and in severe sepsis. Talactoferrin is currently in Phase
III clinical trials in non-small cell lung cancer, and a Phase II/III
trial with talactoferrin in severe sepsis is underway. Other clinical
development programs include RGB-286638, a multi-targeted kinase
inhibitor in Phase I testing, and a topical gel form of talactoferrin
for diabetic foot ulcers. Agennix's registered seat is in Heidelberg,
Germany. The Company has three sites of operation: Planegg/Munich,
Germany; Princeton, New Jersey and Houston, Texas. For additional
information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed
or implied by such forward-looking statements. Actual results could
differ materially depending on a number of factors, and we caution
investors not to place undue reliance on the forward-looking
statements contained in this press release. Even if the results from
our later stage trials with talactoferrin, including the ongoing
FORTIS-M trial in non-small cell lung cancer, are considered
positive, there can be no guarantee that they will be sufficient to
gain marketing approval in the United States or any other country,
and regulatory authorities may require additional information, data
and/or further pre-clinical or clinical studies to support approval.
In such event, there can be no guarantee that the Company will have
or be able to obtain the financial resources to conduct any such
additional studies or that such studies will yield results sufficient
for approval. Forward-looking statements speak only as of the date on
which they are made and Agennix undertakes no obligation to update
these forward-looking statements, even if new information becomes
available in the future.

Agennix(TM) is a trademark of the Agennix group.
Tarceva® is a registered trademark of OSI Pharmaceuticals, Inc.

Further inquiry note:
Barbara Mueller
Manager, Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Senior Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contact for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: ir@agennix.com
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English